BioCryst Pharmaceuticals (BCRX) to Release Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) will likely be releasing its earnings data before the market opens on Monday, February 24th. Analysts expect BioCryst Pharmaceuticals to post earnings of ($0.06) per share and revenue of $131.10 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

BioCryst Pharmaceuticals Stock Up 2.6 %

BioCryst Pharmaceuticals stock opened at $9.05 on Monday. The business’s 50-day simple moving average is $7.86 and its 200 day simple moving average is $7.77. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -14.84 and a beta of 1.75. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $9.11.

Analyst Ratings Changes

Several research firms recently issued reports on BCRX. Evercore ISI raised their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Needham & Company LLC raised their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. Barclays raised their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.